ArticleBlood research2026
Letermovir for cytomegalovirus prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation: a single-center experience.
Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLetermovir prophylaxis results in a significantly lower risk of clinically significant cytomegalovirus (CMV) infection in adult hematopoietic stem cell transplant recipients. However, studies supporting its efficacy in pediatric patients are limited.
methodsWe retrospectively reviewed the outcomes of ten patients who underwent allogeneic hematopoietic stem cell transplantation and received letermovir prophylaxis between November 2021 and October 2024 at our institution.
resultsAmong the ten patients, six donors were CMV-seropositive, whereas nine recipients were CMV-seropositive. Six patients (60%) underwent transplantation from mismatched unrelated donors, and two (20%) from haploidentical donors. Five patients (50%) developed acute graft-versus-host disease (GvHD) > grade 2. Ten patients received letermovir prophylaxis for a median of 101.5 days (range, 26-279). The median daily letermovir dose was 4.6 mg/kg (range, 3.5-11.1 mg/kg), with concomitant use of cyclosporin in nine patients. Eight patients (80%) received letermovir as primary prophylaxis, and two (20%) received it as secondary prophylaxis. None of the patients treated with letermovir as primary prophylaxis had CMV reactivation even after discontinuation (median follow-up, 154 days after transplantation, range 37-850). Both patients who received letermovir as secondary prophylaxis showed CMV reactivation. None of the patients developed CMV infection. No significant adverse effects resulting from the letermovir treatment were observed.
conclusionOur data support the feasibility of letermovir prophylaxis in pediatric patients. The optimal dose of letermovir in pediatric patients has not been established. Letermovir, used as secondary prophylaxis in pediatric patients, was well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.